Gastrointestinal Cancer

Nevertheless, several challenges remain, including receptor heterogeneity, physiologic uptake in normal tissues, optimization of pharmacokinetics, the complexity of dual-targeted constructs, and the lack of high-quality prospective clinical evidence. Future progress will likely depend on ligand engineering, dual-target strategies, individualized dosimetry, and the integration of imaging-based treatment assessment into a closed-loop precision theranostic framework.

Our study suggests that F. nucleatum is associated with cervical cancer malignancy, potentially acting through upregulation of HMGB1 and activation of the canonical NF-κB signaling pathway, thereby contributing to an altered tumor microenvironment. These findings reveal a previously unrecognized microbial-driven oncogenic mechanism in cervical cancer and highlight its potential as a prognostic marker and a therapeutic target.

P2, N=18, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: May 2026 --> Aug 2026

P=N/A, N=278, Not yet recruiting, Affiliated Hospital of Qinghai University

P=N/A, N=36, Recruiting, Dartmouth-Hitchcock Medical Center | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Sep 2027

Despite the initiation of corticosteroids and methotrexate, the patient showed clinical deterioration over four weeks...Following neoadjuvant chemotherapy, surgery, and radiation, the patient achieved complete remission of her myositis, with normalisation of creatine phosphokinase (CPK) levels, resolution of rash, and recovery of muscle strength, confirming the paraneoplastic aetiology. This case underscores the imperative to pursue malignancy screening in DM patients unresponsive to immunosuppressive therapy, regardless of age. It highlights the critical role of thorough physical examination and the superiority of breast imaging in young women with dense breasts.

P=N/A, N=200, Not yet recruiting, Masonic Cancer Center, University of Minnesota

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors (such as palbociclib, ribociclib, and abemaciclib) exert their effects by arresting the cell cycle at the G1/S checkpoint. From the perspective of laboratory medicine, we further emphasize the importance of biomarker detection, therapeutic target assessment, and precision molecular subtyping in identifying patients most likely to benefit from CDK4/6 inhibitor-based therapies. In addition, we discuss the role of these agents in remodeling the TIME, evaluate current combination strategies aimed at overcoming resistance, and highlight future directions for advancing this rapidly evolving field.

The biomarker data supported the mechanism of action involving the upregulation of CD8+ T cells and NK cells. ClinicalTrials.gov Identifier: NCT05104567.

P=N/A, N=50, Not yet recruiting, Peking University Cancer Hospital & Institute

P=N/A, N=30, Not yet recruiting, Ludwig Boltzmann Institute for Digital Health and Prevention

P=N/A, N=600, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Sep 2029 --> Jul 2028 | Trial primary completion date: Sep 2028 --> Jun 2028